26. Metkus, T. S. Myocardial injury in severe COVID-19 compared with non-COVID-19 acute respiratory distress syndrome / T. S. Metkus, L. J. Sokoll, A. S. Barth, M. J. Czarny, A. G. Hays, C. J. Lowenstein et al. // Circulation. – 2021. – V. 6. – № 143. – P. 553–65.
27. Mont, L. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter / L. Mont, R. Elosua, J. Brugada // Europace. – 2009. – № 11. – P. 11–17.
28. O'Connor, M. J. Imaging the it is: endocarditis, myocarditis, and pericarditis / M. J. O'Connor // Curr Opin Cardiol. – 2019. – № 34. – P. 57–64.
29. Pan, D. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review / D. Pan, S. Sze, J. S. Minhas et al. // EClinicalMedicine. – 2020. – № 23. – P. 100404.
30. Patel, P. Ethnicity and covid-19 / P. Patel, L. Hiam, A. Sowemimo et al. // BMJ. – 2020. – № 369. – P. 2282.
31. Pathogeneses of sudden cardiac death in National Collegiate Athletic Association athletes Circ / K. G. Harmon, J. A. Drezner, J. J. Maleszewski et al. // Arrhythm Electrophysiol. – 2014. – № 7. – P. 198–204.
32. Patriki, D. Approximation of the incidence of myocarditis by systematic screening with cardiac magnetic resonance imaging / D. Patriki, E. Gresser, R. Manka, M. Y. Emmert, T. F. Luscher, B. Heidecker // J Am Coll Cardiol HF. – 2018. – № 6. – P. 573–579.
33. Pelliccia, A. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology / A. Pelliccia, R. Fagard, H. H. Bjørnstad et al. // Eur Heart J. – 2005. – № 26. – P. 1422–1445.
34. Pelliccia, A. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC) / A. Pelliccia, E. E. Solberg, M. Papadakis et al. // Eur Heart J. – 2019. – № 40. – P. 19–33.
35. Pelliccia, A. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis / A. Pelliccia, D. Corrado, H. H. Bjørnstad et al. // Eur J Cardiovasc Prev Rehabil. – 2016. – № 13. – P. 876–885.
36. Pelliccia, A. ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease / A. Pelliccia, S. Sharma, S. Gati, M. Bäck, M. Börjesson, Caselli et al. // Eur Heart J. – 2021. – V. 42. – P. 17–96.
37. Piepoli, M. F. Exercise training in heart failure: from theory to practice: a consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation / M. F. Piepoli, V. Conraads, U. Corra et al. // Eur J Heart Fail. – 2013. – № 13. – P. 347–357.
38. Pilgrim, J. L. Cocaine in sudden and unexpected death: a review of 49 post-mortem cases / J. L. Pilgrim, N. Woodford, O. H. Drummer // Forensic Sci Int. – 2013. – V. 227. – P. 52–59.
39. Sagar, S. Myocarditis / S. Sagar, P. P. Liu, L. T. Cooper // Lancet. – 2012. – № 379. – P. 738–747.
40. Saito, J. Electrical remodeling of the ventricular myocardium in myocarditis / J. Saito, S. Niwano, H. Niwano et al. // Circ J. – 2002. – № 66. – P. 97–103.
41. Schellhorn, P. Return to sports after COVID-19 infection / P. Schellhorn, K. Klingel, C. Burgstahler // Eur Heart J. – 2020. – № 41. – P. 4382–4.
42. Schnell, F. Recognition and significance of pathological T-wave inversions in athletes / F. Schnell, N. Riding, R. O'Hanlon et al. // Circulation. – 2015. – № 131. – P. 165–173.
43. Sedaghat-Hamedani, F. Biomarker changes after strenuous exercise can mimic pulmonary embolism and cardiac injury-a meta-analysis of 45 studies / F. Sedaghat-Hamedani, E. Kayvanpour, L. Frankenstein et al. // Clin Chem. – 2015. – № 61. – P. 1246–1255.
44. Shi, S. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China / S. Shi, M. Qin, B. Shen et al. // JAMA Cardiol. – 2020. – № 5. – P. 802–0.
45. Sports-related sudden cardiac death in Switzerland classified by static and dynamic components of exercise / C. Grani, N. Chappex, T. Fracasso et al. // Eur J Prev Cardiol. – 2016. – № 23. – P. 1228–1236.
46. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March-June / M. W. Tenforde, S. S. Kim, C. J. Lindsell et al. // MMWR Morb Mortal Wkly Rep. – 2020. – V. 30. – № 69. – P. 993–8.
47. Tahir, E. Myocardial fibrosis in competitive triathletes detected by contrast-enhanced CMR correlates with exercise-induced hypertension and competition history / E. Tahir, J. Starekova, K. Muellerleile et al. // J Am Coll Cardiol Img. – 2018. – № 11. – P. 1260–1270.
48. Tersalvi, G. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms / G. Tersalvi, M. Vicenzi, D. Calabretta et al. // J Card Fail. – 2020. – № 26. – P. 470–5.
49. Vassalini, M. De Ferrari An autopsy study of sudden cardiac death in persons aged 1-40 years in Brescia (Italy) / M. Vassalini, A. Verzeletti, M. Restori, // J Cardiovasc Med (Hagerstown). – 2016. – № 17. – P. 446–453.
50. Wilson, M. G. Cardiorespiratory considerations for return – play in elite athletes after COVID-19 infection: a practical guide for sport and exercise medicine physicians / M. G. Wilson, J. H. Hull, J. Rogers et al. // Br J Sports Med. – 2020. – V. 54. – № 19. – P. 1157–1161.
51. Wu, C. Causes of troponin elevation and associated mortality in young patients / C. Wu, A. Singh, B. Collins, et al. // Am J Med. – 2018. – № 131. – P. 284–292.
52. Yang, F. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis / F. Yang, J. Wang, W. Li et al. // Eur Radiol. – 2020. – № 30. – P. 2616–26.
Глава 5
Артериальная гипертензия у спортсменов
Артериальная гипертензия (АГ) является ведущим фактором риска развития сердечно-сосудистых (инфаркт миокарда, ишемическая болезнь сердца, хроническая сердечная недостаточность), цереброваскулярных (ишемический или геморрагический инсульт, транзиторная ишемическая атака) и почечных (хроническая болезнь почек) заболеваний. АГ не только является одним из наиболее распространенных заболеваний в популяции, но также связана с увеличением сердечно-сосудистой заболеваемости и более высокой смертностью от всех причин.
